The triple-negative breast cancer (TNBC) subtype does not express molecular markers such as estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) that are the basis of targeted therapies in other molecular subtypes of breast cancer [3,4]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.